Award
National Institute of Allergy and Infectious Diseases 5R43AI188690-02
Development of well tolerated novel Inhibitors of drug resistant CMV
Recipient
MICROBIOTIX, INC
Award Amount
$289,318.00
Ceiling
$289,318.00
Awarded
August 03, 2026
Identifier
5R43AI188690-02
Award to MICROBIOTIX, INC for developing novel inhibitors targeting drug-resistant CMV, focusing on optimizing NAPA compounds for efficacy and safety, with a funding amount of $289,318.
Description
This project aims to develop novel drugs targeting early CMV replication stages, specifically a non-nucleoside N-arylpyrimidinamine (NAPA) compound, MBXC-4302, with potent anti-CMV activity. The project involves chemical optimization of NAPA series to generate 2-4 lead candidates, evaluate their efficacy in vitro and in vivo, and establish pharmacokinetics and tolerability in mice. The goal is to produce well-tolerated therapeutics active against drug-resistant CMV strains.